Table of Contents Author Guidelines Submit a Manuscript
Mediators of Inflammation
Volume 2010 (2010), Article ID 581837, 9 pages
http://dx.doi.org/10.1155/2010/581837
Review Article

Toll-Like Receptors, Tissue Injury, and Tumourigenesis

Department of Pathophysiology, Medical School, National University of Athens, 75 Mikras Asias Street, 11527 Athens, Greece

Received 2 December 2009; Accepted 6 August 2010

Academic Editor: Kathy Triantafilou

Copyright © 2010 Savvas Ioannou and Michael Voulgarelis. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. K. Takeda, T. Kaisho, and S. Akira, “Toll-like receptors,” Annual Review of Immunology, vol. 21, pp. 335–376, 2003. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  2. L. J. Picker and E. C. Butcher, “Physiological and molecular mechanisms of lymphocyte homing,” Annual Review of Immunology, vol. 10, pp. 561–591, 1992. View at Google Scholar · View at Scopus
  3. J. M. Blander and R. Medzhitov, “Regulation of phagosome maturation by signals from Toll-like receptors,” Science, vol. 304, no. 5673, pp. 1014–1018, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  4. M. Schnare, G. M. Barton, A. C. Holt, K. Takeda, S. Akira, and R. Medzhitov, “Toll-like receptors control activation of adaptive immune responses,” Nature Immunology, vol. 2, no. 10, pp. 947–950, 2001. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  5. M.-F. Tsan, “Toll-like receptors, inflammation and cancer,” Seminars in Cancer Biology, vol. 16, no. 1, pp. 32–37, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  6. G. K. Hansson and K. Edfeldt, “Toll to be paid at the gateway to the vessel wall,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 25, no. 6, pp. 1085–1087, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  7. S. Akira and K. Takeda, “Toll-like receptor signalling,” Nature Reviews Immunology, vol. 4, no. 7, pp. 499–511, 2004. View at Google Scholar · View at Scopus
  8. E. M. El-Omar, M. T. Ng, and G. L. Hold, “Polymorphisms in Toll-like receptor genes and risk of cancer,” Oncogene, vol. 27, no. 2, pp. 244–252, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  9. K. Chochi, T. Ichikura, M. Kinoshita et al., “Helicobacter pylori augments growth of gastric cancers via the lipopolysaccharide-toll-like receptor 4 pathway whereas Its lipopolysaccharide attenuates antitumor activities of human mononuclear cells,” Clinical Cancer Research, vol. 14, no. 10, pp. 2909–2917, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  10. T. B. Jelavić, M. Barišić, I. D. Hofman et al., “Microsatellite GT polymorphism in the toll-like receptor 2 is associated with colorectal cancer,” Clinical Genetics, vol. 70, no. 2, pp. 156–160, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  11. T. Tahara, T. Arisawa, F. Wang et al., “Toll-like receptor 2 - 196 to 174del polymorphism influences the susceptibility of Japanese people to gastric cancer,” Cancer Science, vol. 98, no. 11, pp. 1790–1794, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  12. A. Nieters, L. Beckmann, E. Deeg, and N. Becker, “Gene polymorphisms in Toll-like receptors, interleukin-10, and interleukin-10 receptor alpha and lymphoma risk,” Genes and Immunity, vol. 7, no. 8, pp. 615–624, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  13. X.-X. Zhou, W.-H. Jia, G.-P. Shen et al., “Sequence variants in toll-like receptor 10 are associated with nasopharyngeal carcinoma risk,” Cancer Epidemiology Biomarkers and Prevention, vol. 15, no. 5, pp. 862–866, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  14. V. L. Stevens, A. W. Hsing, J. T. Talbot et al., “Genetic variation in the toll-like receptor gene cluster (TLR10-TLR1-TLR6) and prostate cancer risk,” International Journal of Cancer, vol. 123, no. 11, pp. 2644–2650, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  15. C. A. Janeway Jr. and R. Medzhitov, “Innate immune recognition,” Annual Review of Immunology, vol. 20, pp. 197–216, 2002. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  16. M.-F. Tsan and B. Gao, “Endogenous ligands of Toll-like receptors,” Journal of Leukocyte Biology, vol. 76, no. 3, pp. 514–519, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  17. K. Miyake, “Innate immune sensing of pathogens and danger signals by cell surface Toll-like receptors,” Seminars in Immunology, vol. 19, no. 1, pp. 3–10, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  18. M. S. Lee and Y.-J. Kim, “Signaling pathways downstream of pattern-recognition receptors and their cross talk,” Annual Review of Biochemistry, vol. 76, pp. 447–480, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  19. F. Re and J. L. Strominger, “Heterogeneity of TLR-induced responses in dendritic cells: from innate to adaptive immunity,” Immunobiology, vol. 209, no. 1-2, pp. 191–198, 2004. View at Publisher · View at Google Scholar · View at Scopus
  20. E. P. McDermott and L. A. J. O'Neill, “Ras participates in the activation of p38 MAPK by interleukin-1 by associating with IRAK, IRAK2, TRAF6, and TAK-1,” The Journal of Biological Chemistry, vol. 277, no. 10, pp. 7808–7815, 2002. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  21. M. H. Nyirenda, K. O'Brien, L. Sanvito, C. S. Constantinescu, and B. Gran, “Modulation of regulatory T cells in health and disease: role of toll-like receptors,” Inflammation and Allergy—Drug Targets, vol. 8, no. 2, pp. 124–129, 2009. View at Publisher · View at Google Scholar · View at Scopus
  22. L. Milkova, V. Voelcker, I. Forstreuter et al., “The NF-kappaB signaling pathway is involved in the LPS/IL-2-induced upregulation of FoxP3 expression in human CD4CD25 regulatory T cells,” Experimental Dermatology. In press.
  23. L. Macedo, G. Pinhal-Enfield, V. Alshits, G. Elson, B. N. Cronstein, and S. J. Leibovich, “Wound healing is impaired in MyD88-deficient mice: a role for MyD88 in the regulation of wound healing by adenosine A2A receptors,” American Journal of Pathology, vol. 171, no. 6, pp. 1774–1788, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  24. D. Jiang, J. Liang, J. Fan et al., “Regulation of lung injury and repair by Toll-like receptors and hyaluronan,” Nature Medicine, vol. 11, no. 11, pp. 1173–1179, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  25. A. Tsung, R. Sahai, H. Tanaka et al., “The nuclear factor HMGB1 mediates hepatic injury after murine liver ischemia-reperfusion,” Journal of Experimental Medicine, vol. 201, no. 7, pp. 1135–1143, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  26. J.-I. Oyama, C. Blais Jr., X. Liu et al., “Reduced myocardial ischemia-reperfusion injury in Toll-like receptor 4-deficient mice,” Circulation, vol. 109, no. 6, pp. 784–789, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  27. A. Tsung, N. Zheng, G. Jeyabalan et al., “Increasing numbers of hepatic dendritic cells promote HMGB1-mediated ischemia-reperfusion injury,” Journal of Leukocyte Biology, vol. 81, no. 1, pp. 119–128, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  28. L. M. Colletti, D. G. Remick, G. D. Burtch, S. L. Kunkel, R. M. Strieter, and D. A. Campbell Jr., “Role of tumor necrosis factor-α in the pathophysiologic alterations after hepatic ischemia/reperfusion injury in the rat,” Journal of Clinical Investigation, vol. 85, no. 6, pp. 1936–1943, 1990. View at Google Scholar · View at Scopus
  29. H. A. Rüdiger and P. Clavien, “Tumor necrosis factor α, but not Fas, mediates hepatocellular apoptosis in the murine ischemic liver,” Gastroenterology, vol. 122, no. 1, pp. 202–210, 2002. View at Google Scholar · View at Scopus
  30. M. Fukata, A. Chen, A. Klepper et al., “Cox-2 is regulated by Toll-like receptor-4 (TLR4) signaling: role in proliferation and apoptosis in the intestine,” Gastroenterology, vol. 131, no. 3, pp. 862–877, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  31. R. Pai, B. Soreghan, I. L. Szabo, M. Pavelka, D. Baatar, and A. S. Tarnawski, “Prostaglandin E2, transactivates EGF receptor: a novel mechanism for promoting colon cancer growth and gastrointestinal hypertrophy,” Nature Medicine, vol. 8, no. 3, pp. 289–293, 2002. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  32. M. Ramanathan, G. Pinhal-Enfield, I. Hao, and S. J. Leibovich, “Synergistic up-regulation of vascular endothelial growth factor (VEGF) expression in macrophages by adenosine A2A receptor agonists and endotoxin involves transcriptional regulation via the hypoxia response element in the VEGF promoter,” Molecular Biology of the Cell, vol. 18, no. 1, pp. 14–23, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  33. E. Seki, S. De Minicis, C. H. Österreicher et al., “TLR4 enhances TGF-β signaling and hepatic fibrosis,” Nature Medicine, vol. 13, no. 11, pp. 1324–1332, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  34. Y.-H. Paik, R. F. Schwabe, R. Bataller, M. P. Russo, C. Jobin, and D. A. Brenner, “Toll-like receptor 4 mediates inflammatory signaling by bacterial lipopolysaccharide in human hepatic stellate cells,” Hepatology, vol. 37, no. 5, pp. 1043–1055, 2003. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  35. Y.-H. Paik, K. S. Lee, H. J. Lee et al., “Hepatic stellate cells primed with cytokines upregulate inflammation in response to peptidoglycan or lipoteichoic acid,” Laboratory Investigation, vol. 86, no. 7, pp. 676–686, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  36. S. Ghosh and M. Karin, “Missing pieces in the NF-κB puzzle,” Cell, vol. 109, supplement, pp. S81–S96, 2002. View at Publisher · View at Google Scholar · View at Scopus
  37. I. Becker, N. Salaiza, M. Aguirre et al., “Leishmania lipophosphoglycan (LPG) activates NK cells through toll-like receptor-2,” Molecular and Biochemical Parasitology, vol. 130, no. 2, pp. 65–74, 2003. View at Publisher · View at Google Scholar · View at Scopus
  38. B. Huang, J. Zhao, H. Li et al., “Toll-like receptors on tumor cells facilitate evasion of immune surveillance,” Cancer Research, vol. 65, no. 12, pp. 5009–5014, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  39. M. G. Kelly, A. B. Alvero, R. Chen et al., “TLR-4 signaling promotes tumor growth and paclitaxel chemoresistance in ovarian cancer,” Cancer Research, vol. 66, no. 7, pp. 3859–3868, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  40. B. Huang, J. Zhao, S. Shen et al., “Listeria monocytogenes promotes tumor growth via tumor cell toll-like receptor 2 signaling,” Cancer Research, vol. 67, no. 9, pp. 4346–4352, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  41. W. He, Q. Liu, L. Wang, W. Chen, N. Li, and X. Cao, “TLR4 signaling promotes immune escape of human lung cancer cells by inducing immunosuppressive cytokines and apoptosis resistance,” Molecular Immunology, vol. 44, no. 11, pp. 2850–2859, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  42. C. Nakanishi and M. Toi, “Nuclear factor-κB inhibitors as sensitizers to anticancer drugs,” Nature Reviews Cancer, vol. 5, no. 4, pp. 297–309, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  43. S. Kreuz, D. Siegmund, J.-J. Rumpf et al., “NFκB activation by Fas is mediated through FADD, caspase-8, and RIP and is inhibited by FLIP,” Journal of Cell Biology, vol. 166, no. 3, pp. 369–380, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  44. M. Fukata, A. Chen, A. S. Vamadevan et al., “Toll-like receptor-4 promotes the development of colitis-associated colorectal tumors,” Gastroenterology, vol. 133, no. 6, pp. 1869–1881, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  45. S. Rakoff-Nahoum and R. Medzhitov, “Regulation of spontaneous intestinal tumorigenesis through the adaptor protein MyD88,” Science, vol. 317, no. 5834, pp. 124–127, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  46. H. F. Dvorak, “Tumors: wounds that do not heal: similarities between tumor stroma generation and wound healing,” The New England Journal of Medicine, vol. 315, no. 26, pp. 1650–1659, 1986. View at Google Scholar · View at Scopus
  47. K. D. Taganov, M. P. Boldin, K.-J. Chang, and D. Baltimore, “NF-κB-dependent induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune responses,” Proceedings of the National Academy of Sciences of the United States of America, vol. 103, no. 33, pp. 12481–12486, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  48. B. Salaun, I. Coste, M.-C. Rissoan, S. J. Lebecque, and T. Renno, “TLR3 can directly trigger apoptosis in human cancer cells,” Journal of Immunology, vol. 176, no. 8, pp. 4894–4901, 2006. View at Google Scholar · View at Scopus
  49. G. Gannot, I. Gannot, H. Vered, A. Buchner, and Y. Keisari, “Increase in immune cell infiltration with progression of oral epithelium from hyperkeratosis to dysplasia and carcinoma,” British Journal of Cancer, vol. 86, no. 9, pp. 1444–1448, 2002. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  50. J. Condeelis and J. W. Pollard, “Macrophages: obligate partners for tumor cell migration, invasion, and metastasis,” Cell, vol. 124, no. 2, pp. 263–266, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  51. S. Kim, H. Takahashi, W.-W. Lin et al., “Carcinoma-produced factors activate myeloid cells through TLR2 to stimulate metastasis,” Nature, vol. 457, no. 7225, pp. 102–106, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  52. N. Satta, E. K. O. Kruithof, G. Reber, and P. de Moerloose, “Induction of TLR2 expression by inflammatory stimuli is required for endothelial cell responses to lipopeptides,” Molecular Immunology, vol. 46, no. 1, pp. 145–157, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  53. D. J. J. Waugh and C. Wilson, “The interleukin-8 pathway in cancer,” Clinical Cancer Research, vol. 14, no. 21, pp. 6735–6741, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  54. W. Wang, G.-L. Xu, W.-D. Jia et al., “Ligation of TLR2 by versican: a link between inflammation and metastasis,” Archives of Medical Research, vol. 40, no. 4, pp. 321–323, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  55. A. Nowotny, “Antitumor effects of endotoxins,” in Handbook of Endotoxin, L. J. Berry, Ed., vol. 3 of Cellular Biology of Endotoxin, pp. 389–448, Elsevier, Amsterdam, The Netherlands, 2nd edition, 1985. View at Google Scholar
  56. M. J. Berendt, R. J. North, and D. P. Kirstein, “The immunological basis of endotoxin induced tumor regression. Requirement for T cell mediated immunity,” Journal of Experimental Medicine, vol. 148, no. 6, pp. 1550–1559, 1978. View at Google Scholar · View at Scopus
  57. S. Goriely, M. F. Neurath, and M. Goldman, “How microorganisms tip the balance between interleukin-12 family members,” Nature Reviews Immunology, vol. 8, no. 1, pp. 81–86, 2008. View at Publisher · View at Google Scholar · View at PubMed
  58. A. C. I. Boullart, E. H. J. G. Aarntzen, P. Verdijk et al., “Maturation of monocyte-derived dendritic cells with Toll-like receptor 3 and 7/8 ligands combined with prostaglandin E2 results in high interleukin-12 production and cell migration,” Cancer Immunology, Immunotherapy, vol. 57, no. 11, pp. 1589–1597, 2008. View at Publisher · View at Google Scholar · View at PubMed
  59. L. Apetoh, F. Ghiringhelli, A. Tesniere et al., “Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy,” Nature Medicine, vol. 13, no. 9, pp. 1050–1059, 2007. View at Publisher · View at Google Scholar · View at PubMed
  60. R. M. O'Connell, K. D. Taganov, M. P. Boldin, G. Cheng, and D. Baltimore, “MicroRNA-155 is induced during the macrophage inflammatory response,” Proceedings of the National Academy of Sciences of the United States of America, vol. 104, no. 5, pp. 1604–1609, 2007. View at Publisher · View at Google Scholar · View at PubMed
  61. J. Banchereau and R. M. Steinman, “Dendritic cells and the control of immunity,” Nature, vol. 392, no. 6673, pp. 245–252, 1998. View at Publisher · View at Google Scholar · View at PubMed
  62. S. Paczesny, H. Ueno, J. Fay, J. Banchereau, and A. K. Palucka, “Dendritic cells as vectors for immunotherapy of cancer,” Seminars in Cancer Biology, vol. 13, no. 6, pp. 439–447, 2003. View at Publisher · View at Google Scholar · View at PubMed
  63. F. Re and J. L. Strominger, “IL-10 released by concomitant TLR2 stimulation blocks the induction of a subset of Th1 cytokines that are specifically induced by TLR4 or TLR3 in human dendritic cells,” Journal of Immunology, vol. 173, no. 12, pp. 7548–7555, 2004. View at Google Scholar
  64. M. Komai-Koma, L. Jones, G. S. Ogg, D. Xu, and F. Y. Liew, “TLR2 is expressed activated T cells as a costimulatory receptor,” Proceedings of the National Academy of Sciences of the United States of America, vol. 101, no. 9, pp. 3029–3034, 2004. View at Publisher · View at Google Scholar · View at PubMed
  65. R. P. Garay, P. Viens, J. Bauer et al., “Cancer relapse under chemotherapy: why TLR2/4 receptor agonists can help,” European Journal of Pharmacology, vol. 563, no. 1–3, pp. 1–17, 2007. View at Publisher · View at Google Scholar · View at PubMed
  66. M. Okamoto, T. Oshikawa, T. Tano et al., “Involvement of Toll-like receptor 4 signaling in interferon-γ production and antitumor effect by streptococcal agent OK-432,” Journal of the National Cancer Institute, vol. 95, no. 4, pp. 316–326, 2003. View at Google Scholar
  67. T. Tano, M. Okamoto, T. Oshikawa, S. U. Ahmed, A. Sasai, and M. Sato, “Induction of apoptosis in human head and neck cancer cell lines by an active component of OK-432 through p53-independent pathway via toll-like receptor (TLR) 4 signaling,” Gan to Kagaku Ryoho, vol. 32, no. 11, pp. 1562–1564, 2005. View at Google Scholar
  68. V. Oldfield, G. M. Keating, and C. M. Perry, “Imiquimod: in superficial basal cell carcinoma,” American Journal of Clinical Dermatology, vol. 6, no. 3, pp. 195–200, 2005. View at Publisher · View at Google Scholar